Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C19H27NO3 and a molecular weight of approximately 317.42 g/mol[1][2][6]. It is classified as an aromatic benzenoid derivative. The primary mechanism of action identified for this molecule is inhibition of cathepsin K, an enzyme involved in bone resorption[1]. There are no approved indications or clinical trials reported for this compound, and it remains at the experimental stage with no evidence of development beyond preclinical research[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-(phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate.